GSK241122C29000
- 0.00
- 0.000.00%
GlaxoSmithKline Newsroom
GSK Says Trial of Itch Treatment Linerixibat Meets Primary Endpoint
Statement: GSK Continues to Show Strong Leadership in Its Access to Medicines Index Ranking
Linerixibat Shows Positive Phase III Results in Cholestatic Pruritus (Relentless Itch) in Primary Biliary Cholangitis (PBC)
Express News | Us CDC Says Since April Confirmed Avian Influenza A(H5) Virus Infections In 52 People In US; Aware Of Human Case Of H5N1 Bird Flu Reported In Canada & Is In Communication With Public Health Agency Of Canada
Global Companies With at Least 50% U.S. Revenue Exposure as Trump Eyes Tariffs: BofA
Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer
GSK Cut to Hold From Buy by Deutsche Bank
GSK Target Cut to GBP13.50 From GBP17.00 by Deutsche Bank
Trending Stocks This Week as Wall Street Sells off Amid Fed Remarks
US Manufacturing Index Rises To 43, Highest Since 2020
Large Pharmas, Biotechs Down as Industries Grapple With RFK Jr. at HHS
GSK Plc (GSK) Guggenheim's Inaugural Healthcare Innovation Conference (Transcript)
PFE, Moderna Shares Fall As Trump's RFK Pick Weighs on Vaccine Makers
RFK Jr. News Hits Global Pharma Stocks -- WSJ
RFK and the 'MAHA Trade': Vaccine Makers Down, Psychedelic Shares up
Vaccine Sector Sell-Off Looks Overdone -- Market Talk
Stocks to Watch Friday: Tesla, Domino's, Palantir, Ulta -- WSJ
GSK (GSK.US) ADC therapy phase 3 clinical results are positive, extending the lives of patients with refractory cancer.
GSK (GSK.US) announced today that its antibody-drug conjugate (ADC) Blenrep (belantamab mafodotin) has obtained positive results in the interim analysis of the Phase 3 clinical trial DREAMM-7.
Vaccines Makers Close Lower on Reports RFK Jr May Head HHS
GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep To Return To US Market - Here's Why